Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine

Clicks: 386
ID: 120227
2012
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Combining data from the 5 sites strengthens the precision of VE estimates and reveals rising VE with increased RVGE severity. Extrapolating data from VE against severe GE and RVGE suggest that 39% of severe GE episodes during the first year of life were due to rotavirus, highlighting substantial, po …
Reference Key
rf2012vaccineanalyses Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Breiman RF;Zaman K;Armah G;Sow SO;Anh DD;Victor JC;Hille D;Ciarlet M;Neuzil KM;;
Journal Vaccine
Year 2012
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/22520132
Keywords
Administration National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine Infant Clinical Trial Phase III Randomized Controlled Trial Double-Blind Method Multicenter Study Genotype severity of illness index rotavirus infections / epidemiology rotavirus infections / prevention & control* rotavirus vaccines / immunology* vaccines attenuated / administration & dosage attenuated / immunology gastroenteritis / epidemiology gastroenteritis / prevention & control* rotavirus vaccines / administration & dosage* feces / virology rotavirus / isolation & purification developing countries oral asia / epidemiology placebos / administration & dosage vaccination / methods* rotavirus / classification rotavirus / genetics k zaman africa / epidemiology kathleen m neuzil pmid:22520132 doi:10.1016/j.vaccine.2011.08.124 robert f breiman gastroenteritis / pathology rotavirus infections / pathology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.